对Bosniak分类2019版提出的II类囊性肾肿块的评估:支持性证据的系统综述
本系统综述纳入10项研究共2068个肾肿块,评估Bosniak v.2019新增II类亚型中恶性或可能恶性的比例。CT新增4型中,均匀高密度(≥70 HU)为0%(0/32)、均匀9-20 HU为0%(0/1454)、门静脉期21-30 HU为0%(0/454);MRI新增2型中,T2明显高信号为0%(0/72)、T1明显高信号为0%(0/32)和5%(2/37);「均匀低密度且太小无法定性」的CT型无支持证据。
要点
- Bosniak v.2019新增II类中,CT均匀9-20 HU型恶性比例0%(0/1454),证据例数最多。
- CT均匀低密度且太小无法定性型无支持证据,视为良性部分基于专家意见。
- MRI T1明显高信号型恶性比例0%(0/32)和5%(2/37),需注意后者包含恶性。
核心结论
- Bosniak v.2019将六种囊性肾肿块新增为II类可能有其合理性,但证据有限;CT上「均匀低密度且太小无法定性」型无证据,将其视为良性部分基于专家意见。
研究设计与样本
- 系统综述,检索多个数据库,纳入10项研究共2068个肾肿块,评估Bosniak v.2019新增II类亚型(CT 4型、MRI 2型)中恶性或可能恶性的比例,采用QUADAS-2工具评估偏倚风险和适用性,方案注册号PROSERO CRD42020196408。
诊断标准与关键数值
- CT新增II类:均匀高密度(平扫≥70 HU)恶性比例0%(0/32),3项研究。
- CT新增II类:均匀9-20 HU(平扫)恶性比例0%(0/1454),2项研究。
- CT新增II类:均匀21-30 HU(门静脉期)恶性比例0%(0/454),4项研究。
- MRI新增II类:平扫T2WI明显高信号(类似CSF)恶性比例0%(0/72),1项研究。
- MRI新增II类:平扫T1WI明显高信号(约2.5倍肾实质信号强度)恶性比例0%(0/32)和5%(2/37),2项研究。
临床应用与阅片要点
- CT上均匀9-20 HU型有较大样本支持恶性比例0%(0/1454),可参考。
- CT上均匀低密度且太小无法定性型无支持证据,视为良性部分基于专家意见。
- MRI T1明显高信号型中5%(2/37)为恶性,判读时需结合其他特征。
局限性
- 10项研究中有9项在至少一个QUADAS-2领域存在偏倚风险。
- 新增六型II类的证据有限。
- CT上「均匀低密度且太小无法定性」型无支持证据。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
英文原文(摘要)· 点击展开
PURPOSE: The Bosniak classification of cystic renal masses version 2019 (v.2019) includes an expanded number of types of masses in class II; such masses are considered benign in clinical practice. Data supporting these additions have not been well-documented. We aim to determine the proportion of malignant or probably malignant renal masses among the types added to Bosniak v.2019 class II.
METHODS: Multiple databases were searched for studies evaluating the proportion of malignant or probably malignant renal masses among new Bosniak v.2019 class II types, four for CT and two for MRI. Risk of bias and applicability was assessed using the QUADAS-2 tool.
RESULTS: Ten studies (2068 renal masses) met inclusion criteria. Among the four added class II types at CT, the proportion of malignancy among (1) 'homogeneous hyperattenuating (≥ 70 HU) masses at unenhanced CT' was 0% (0/32) in three studies; (2) 'homogeneous masses - 9 to 20 HU at unenhanced CT' was 0% (0/1454) in two studies, and (3) 'homogeneous masses 21 to 30 HU at portal-venous phase CT' was 0% (0/454) in four studies. Masses that are homogeneous, have low attenuation, and are too small to characterize on CT had no supportive evidence. Among the two added class II types at MRI, the proportion of malignancy among (1) 'homogeneous masses markedly hyperintense at unenhanced T2-weighted MR imaging (similar to CSF) was 0% (0/72) in one study, and (2) 'homogeneous masses markedly hyperintense at T1-weighted MR imaging (~ 2.5 × renal parenchyma signal intensity)' was 0% (0/32) and 5% (2/37) in two studies. Nine studies were at risk of bias within at least one QUADAS-2 domain.
CONCLUSION: The addition of six types of cystic renal masses to Class II in the Bosniak v.2019 proposal may be justified but based on limited evidence, with no evidence for 'homogeneous low attenuation masses that are too small to characterize' on CT, and thus considering them benign is in part based on expert opinion. Protocol Registration: PROSERO CRD42020196408.
引用
- McGrath TA, Shoeib A, Davenport MS, et al. Evaluation of class II cystic renal masses proposed in Bosniak classification version 2019: a systematic review of supporting evidence. Abdom Radiol (NY). 2021. PMID: 34152438. doi:10.1007/s00261-021-03180-y
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。